SM2256
/ StarMab Biomed
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2024
SM2256: A bispecific conditional CD40 and 4-1BB dual agonist for enhanced solid tumor immune response
(AACR 2024)
- "SM2256 is a novel conditional CD40 and 4-1BB dual agonist that demonstrates promising preclinical efficacy against solid tumors while boasting an improved safety profile when compared to existing monoclonal antibodies."
IO biomarker • Oncology • Solid Tumor • CD40 • TNFRSF9
1 to 1
Of
1
Go to page
1